GlassScriptPhysician profile
Eva Urtasun Sotil
NPI 1689819856
$5,745.50
in general payments reported to CMS, 2019-2025
36 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,164 · 2020: $218 · 2021: $54.00 · 2022: $422 · 2023: $1,183 · 2024: $1,105 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,788 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,788.10 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,125.94 | 2019-2025 | Livdelzi, Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $804.86 | 2019-2025 | Entyvio, Livtencity |
| Abbvie INC. | $596.77 | 2019-2025 | Linzess, Creon, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.51 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $476.46 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $378.89 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $194.17 | 2023-2024 | Linzess |
| Celgene Corporation | $187.27 | 2022-2024 | Zeposia |
| Mirum Pharmaceuticals, INC. | $176.87 | 2024-2025 | Livmarli |
| Regeneron Healthcare Solutions, INC. | $124.39 | 2023-2024 | Dupixent |
| Madrigal Pharmaceuticals | $112.61 | 2025 | Rezdiffra |
| Qol Medical, LLC | $86.75 | 2025 | Sucraid |
| Merck Sharp & Dohme LLC | $85.01 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $84.06 | 2023-2025 | Rebyota |
| Mallinckrodt Hospital Products INC. | $81.87 | 2024-2025 | Terlivaz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orphalan INC | $81.86 | 2024-2025 | Cuvrior |
| Echosens North America, INC. | $60.85 | 2019-2025 | Fibroscan |
| Allergan, INC. | $56.01 | 2019 | |
| Ardelyx, INC. | $51.82 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $46.10 | 2019-2023 | |
| Fujifilm Healthcare Americas Corporation | $43.23 | 2020-2023 | Utaswako Afp-L3 |
| Veloxis Pharmaceuticals, INC. | $41.89 | 2021-2023 | Envarsus |
| Evoke Pharma, INC. | $38.71 | 2023 | Gimoti |
| Lilly USA, LLC | $36.31 | 2025 | Omvoh |
| Alexion Pharmaceuticals, INC. | $34.75 | 2019 | |
| Celltrion USA INC. | $26.33 | 2025 | Vegzelma |
| Amgen INC. | $22.00 | 2025 | Uplizna |
| Shire North American Group INC | $19.79 | 2019 | |
| Eisai INC. | $18.45 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.89 | 2023 | |
| Dova Pharmaceuticals | $16.04 | 2019 | |
| Shionogi INC | $15.83 | 2019 | |
| Ucb, INC. | $13.49 | 2019 | |
| Braintree Laboratories, INC. | $13.46 | 2025 | Sutab, Suflave |
| Romark Laboratories, Lc | $12.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Urtasun Sotil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.